Replimune

Replimune is a biotechnology company that develops and commercializes immunotherapy treatments for cancer, including a drug for melanoma.

Why it’s in the news: It is in the news because its melanoma drug has been approved by the FDA after being previously rejected twice, following expert review and debate.

Latest on Replimune

• STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
• FDA approves Replimune melanoma drug previously rejected twice
• STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
• STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment
• STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
• <a href="https://www.fiercepharma.com/biotech/fda-refuses-replimunes-melanoma-prospect-second-time" hreflang="en">UPDATED: Replimune to reduce workforce following 'disappointing' second rejection for melanoma prospect</a>

Connections

6 entities linked to Replimune across the news graph.